Allostasis as a conceptual framework linking bipolar disorder and addiction

Frontiers in Psychiatry

Volumn 5, Issue DEC, 2014, Pages

  Pettorruso, Mauro ^a   De Risio, Luisa ^a   Di Nicola, Marco ^a   Martinotti, Giovanni ^b   Conte, Gianluigi ^a   Janiri, Luigi ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Addiction vulnerability; Allostasis and allostatic load; Bipolar disorders; Comorbidity; CRF HPA axis and stress system; Dopaminergic system; Hedonic tone and anhedonia; Reward system

Indexed keywords

ADDICTION; ALLOSTASIS; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; CONCEPTUAL FRAMEWORK; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG DEPENDENCE; EMOTIONALITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEUROBIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; REINFORCEMENT;

EID: 84926426604     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2014.00173     Document Type: Article

References (143)

1. Vornik LA, Brown ES. Management of comorbid bipolar disorder and substance abuse. J Clin Psychiatry (2006) 67(Suppl 7):24-30.
2. Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, Ruan WJ, et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiatry (2005) 66(10):1205-15. doi: 10.4088/JCP.v66n1001
3. Altamura AC. Bipolar spectrum and drug addiction. J Affect Disord (2007) 99(1-3):285. doi:10.1016/j.jad.2006.09.005
4. Di Nicola M, Tedeschi D, Mazza M, Martinotti G, Harnic D, Catalano V, et al. Behavioural addictions in bipolar disorder patients: role of impulsivity and personality dimensions. J Affect Disord (2010) 125(1-3):82-8. doi:10.1016/j.jad.2009.12.016
5. Pettorruso M, Di Nicola M, De Risio L, Fasano A, Martinotti G, Conte G, et al. Punding behavior in bipolar disorder type 1: a case report. J Neuropsychiatry Clin Neurosci (2014) 26(4):E8-9. doi:10.1176/appi.neuropsych.13090217
6. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. JAMA (1990) 264(19):2511-8. doi:10.1001/jama.1990.03450190043026
7. Fagiolini A, Forgione R, Maccari M, Cuomo A, Morana B, Dell'Osso MC, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord (2013) 148(2-3):161-9. doi:10.1016/j.jad.2013.02.001
8. Tsai HC, Lu MK, Yang YK, Huang MC, Yeh TL, Chen WJ, et al. Empirically derived subgroups of bipolar I patients with different comorbidity patterns of anxiety and substance use disorders in Han Chinese population. J Affect Disord (2012) 136(1-2):81-9. doi:10.1016/j.jad.2011.08.015
9. Frye MA, Salloum IM. Bipolar disorder and comorbid alcoholism: prevalence rate and treatment considerations. Bipolar Disord (2006) 8(6):677-85. doi:10.1111/j.1399-5618.2006.00370.x
10. Mazza M, Mandelli L, Di Nicola M, Harnic D, Catalano V, Tedeschi D, et al. Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up. J Affect Disord (2009) 115(1-2):27-35. doi:10.1016/j.jad.2008.08.019
11. Mandelli L, Mazza M, Di Nicola M, Zaninotto L, Harnic D, Catalano V, et al. Role of substance abuse comorbidity and personality on the outcome of depression in bipolar disorder: harm avoidance influences medium-term treatment outcome. Psychopathology (2012) 45(3):174-8. doi:10.1159/000330364
12. McIntyre RS, Nguyen HT, Soczynska JK, Lourenco MT, Woldeyohannes HO, Konarski JZ. Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities. Dialogues Clin Neurosci (2008) 10(2):203-13.
13. Carrà G, Bartoli F, Crocamo C, Brady KT, Clerici M. Attempted suicide in people with co-occurring bipolar and substance use disorders: systematic review and meta-analysis. J Affect Disord (2014) 167:125-35. doi:10.1016/j.jad.2014.05.066
14. Yoon YH, Chen CM, Yi HY, Moss HB. Effect of comorbid alcohol and drug use disorders on premature death among unipolar and bipolar disorder decedents in the United States, 1999 to 2006. Compr Psychiatry (2011) 52(5):453-64. doi:10.1016/j.comppsych.2010.10.005
15. Uhl GR, Drgon T, Johnson C, Li CY, Contoreggi C, Hess J, et al. Molecular genetics of addiction and related heritable phenotypes: genome-wide association approaches identify "connectivity constellation" and drug target genes with pleiotropic effects. Ann N Y Acad Sci (2008) 1141:318-81. doi:10.1196/annals.1441.018
16. Adida M, Jollant F, Clark L, Besnier N, Guillaume S, Kaladjian A, et al. Trait-related decision-making impairment in the three phases of bipolar disorder. Biol Psychiatry (2011) 70(4):357-65. doi:10.1016/j.biopsych.2011.01.018
17. Adinoff B, Rilling LM, Williams MJ, Schreffler E, Schepis TS, Rosvall T, et al. Impulsivity, neural deficits, and the addictions: the "oops" factor in relapse. J Addict Dis (2007) 26(Suppl 1):25-39. doi:10.1300/J069v26S01_04
18. Ahn WY, Rass O, Fridberg DJ, Bishara AJ, Forsyth JK, Breier A, et al. Temporal discounting of rewards in patients with bipolar disorder and schizophrenia. J Abnorm Psychol (2011) 120(4):911-21. doi:10.1037/a0023333
19. Swann AC. The strong relationship between bipolar and substance-use disorder. Ann N Y Acad Sci (2010) 1187:276-93. doi:10.1111/j.1749-6632.2009.05146.x
20. Sterling P, Eyer J. Allostasis: a new paradigm to explain arousal pathology. In: Fisher S, Reason J, editors. Handbook of Life Stress, Cognition and Health. Chichester: John Wiley (1988). p. 629-49.
21. McEwen BS. Stress, adaptation, and disease. Allostasis and allostatic load. Ann N Y Acad Sci (1998) 840:33-44. doi:10.1111/j.1749-6632.1998.tb09546.x
22. McEwen BS. Allostasis and allostatic load: implications for neuropsychopharmacology. Neuropsychopharmacology (2000) 22(2):108-24. doi:10.1016/S0893-133X(99)00129-3
23. Brietzke E, Mansur RB, Soczynska J, Powell AM, McIntyre RS. A theoretical framework informing research about the role of stress in the pathophysiology of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry (2012) 39(1):1-8. doi:10.1016/j.pnpbp.2012.05.004
24. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev (2008) 32(4):675-92. doi:10.1016/j.neubiorev.2007.10.005
25. Grande I, Magalhães PV, Kunz M, Vieta E, Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol Behav (2012) 106(1):46-50. doi:10.1016/j.physbeh.2011.10.029
26. Vieta E, Popovic D, Rosa AR, Solé B, Grande I, Frey BN, et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur Psychiatry (2013) 28(1):21-9. doi:10.1016/j.eurpsy.2011.11.007
27. Angelucci F, Ricci V, Gelfo F, Martinotti G, Brunetti M, Sepede G, et al. BDNF serum levels in subjects developing or not post-traumatic stress disorder after trauma exposure. Brain Cogn (2014) 84(1):118-22. doi:10.1016/j.bandc.2013.11.012
28. Kapczinski F, Frey BN, Kauer-Sant'Anna M, Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother (2008) 8(7):1101-13. doi:10.1586/14737175.8.7.1101
29. Mandelli L, Mazza M, Martinotti G, Tavian D, Colombo E, Missaglia S, et al. Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance. J Psychopharmacol (2010) 24(12):1747-54. doi:10.1177/0269881109353463
30. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev (2011) 35(3):804-17. doi:10.1016/j.neubiorev.2010.10.001
31. Grande I, Magalhães PV, Chendo I, Stertz L, Panizutti B, Colpo GD, et al. Staging systems in bipolar disorder: an International society for bipolar disorders task force report. Acta Psychiatr Scand (2014) 130(5):354-63. doi:10.1111/acps.12268
32. Schulkin J. Allostasis: a neural behavioral perspective. Horm Behav (2003) 43(1):21-7. doi:10.1016/S0018-506X(02)00035-1
33. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev (2005) 4(2):141-94. doi:10.1016/j.arr.2005.03.003
34. Andreazza AC, Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord (2008) 111(2-3):135-44. doi:10.1016/j.jad.2008.04.013
35. Steen NE, Methlie P, Lorentzen S, Hope S, Barrett EA, Larsson S, et al. Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability? J Clin Psychiatry (2011) 72(11):1515-21. doi:10.4088/JCP.10m06068yel
36. Steen NE, Methlie P, Lorentzen S, Dieset I, Aas M, Nerhus M, et al. Altered systemic cortisol metabolism in bipolar disorder and schizophrenia spectrum disorders. J Psychiatr Res (2014) 52:57-62. doi:10.1016/j.jpsychires.2014.01.017
37. Daban C, Vieta E, Mackin P, Young AH. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am (2005) 28(2):469-80. doi:10.1016/j.psc.2005.01.005
38. Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry (2004) 184:496-502. doi:10.1192/bjp.184.6.496
39. McEwen BS. Structural plasticity of the adult brain: how animal models help us understand brain changes in depression and systemic disorders related to depression. Dialogues Clin Neurosci (2004) 6(2):119-33.
40. McEwen BS. Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol (2008) 583(2-3):174-85. doi:10.1016/j.ejphar.2007.11.071
41. Altman S, Haeri S, Cohen LJ, Ten A, Barron E, Galynker II, et al. Predictors of relapse in bipolar disorder: a review. J Psychiatr Pract (2006) 12(5):269-82. doi:10.1097/00131746-200609000-00002
42. Horesh N, Apter A, Zalsman G. Timing, quantity and quality of stressful life events in childhood and preceding the first episode of bipolar disorder. J Affect Disord (2011) 134(1-3):434-7. doi:10.1016/j.jad.2011.05.034
43. Lai MC, Huang LT. Effects of early life stress on neuroendocrine and neurobehavior: mechanisms and implications. Pediatr Neonatol (2011) 52(3):122-9. doi:10.1016/j.pedneo.2011.03.008
44. Baker LM, Williams LM, Korgaonkar MS, Cohen RA, Heaps JM, Paul RH. Impact of early vs. late childhood early life stress on brain morphometrics. Brain Imaging Behav (2013) 7(2):196-203. doi:10.1007/s11682-012-9215-y
45. Linke J, King AV, Rietschel M, Strohmaier J, Hennerici M, Gass A, et al. Increased medial orbitofrontal and amygdala activation: evidence for a systems-level endophenotype of bipolar I disorder. Am J Psychiatry (2012) 169(3):316-25. doi:10.1176/appi.ajp.2011.11050711
46. Koob GF, Buck CL, Cohen A, Edwards S, Park PE, Schlosburg JE, et al. Addiction as a stress surfeit disorder. Neuropharmacology (2014) 76(Pt B):370-82. doi:10.1016/j.neuropharm.2013.05.024
47. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology (2001) 24(2):97-129. doi:10.1016/S0893-133X(00)00195-0
48. Koob GF. Addiction is a reward deficit and stress surfeit disorder. Front Psychiatry (2013) 4:72. doi:10.3389/fpsyt.2013.00072
49. George O, Le Moal M, Koob GF. Allostasis and addiction: role of the dopamine and corticotropin-releasing factor systems. Physiol Behav (2012) 106(1):58-64. doi:10.1016/j.physbeh.2011.11.004
50. Koob G, Kreek MJ. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry (2007) 164(8):1149-59. doi:10.1176/appi.ajp.2007.05030503
51. Pettorruso M, Martinotti G, Fasano A, Loria G, Di Nicola M, De Risio L, et al. Anhedonia in Parkinson's disease patients with and without pathological gambling: a case-control study. Psychiatry Res (2014) 215(2):448-52. doi:10.1016/j.psychres.2013.12.013
52. Koob GF. Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology (2009) 56(Suppl 1):18-31. doi:10.1016/j.neuropharm.2008.07.043
53. Gilpin NW. Brain reward and stress systems in addiction. Front Psychiatry (2014) 5:79. doi:10.3389/fpsyt.2014.00079
54. Koob GF. A role for brain stress systems in addiction. Neuron (2008) 59(1):11-34. doi:10.1016/j.neuron.2008.06.012
55. Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol (2008) 59:29-53. doi:10.1146/annurev.psych.59.103006.093548
56. Koob GF. Hedonic homeostatic dysregulation as a driver of drug-seeking behavior. Drug Discov Today Dis Models (2008) 5(4):207-15. doi:10.1016/j.ddmod.2009.04.002
57. Koob GF. Neuroadaptive mechanisms of addiction: studies on the extended amygdala. Eur Neuropsychopharmacol (2003) 13(6):442-52. doi:10.1016/j.euroneuro.2003.08.005
58. Koob GF. The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res (2010) 1314:3-14. doi:10.1016/j.brainres.2009.11.008
59. Martinotti G, Nicola MD, Reina D, Andreoli S, Focà F, Cunniff A, et al. Alcohol protracted withdrawal syndrome: the role of anhedonia. Subst Use Misuse (2008) 43(3-4):271-84. doi:10.1080/10826080701202429
60. Valdez GR, Koob GF. Allostasis and dysregulation of and neuropeptide Y systems: implications for the development of alcoholism. Pharmacol Biochem Behav (2004) 79(4):671-89. doi:10.1016/j.pbb.2004.09.020
61. Carmiol N, Peralta JM, Almasy L, Contreras J, Pacheco A, Escamilla MA, et al. Shared genetic factors influence risk for bipolar disorder and alcohol use disorders. Eur Psychiatry (2014) 29(5):282-7. doi:10.1016/j.eurpsy.2013.10.001
62. Mandelli L, Mazza M, Marangoni C, Di Nicola M, Martinotti G, Tavian D, et al. Preliminary analysis of genes involved in inflammatory, oxidative processes and CA2+signaling in bipolar disorder and comorbidity for substance use disorder. Clin Neuropsychiatry (2011) 8(6):347-53.
63. Johnson C, Drgon T, McMahon FJ, Uhl GR. Convergent genome wide association results for bipolar disorder and substance dependence. Am J Med Genet B Neuropsychiatr Genet (2009) 150B(2):182-90. doi:10.1002/ajmg.b.30900
64. Levey DF, Le-Niculescu H, Frank J, Ayalew M, Jain N, Kirlin B, et al. Genetic risk prediction and neurobiological understanding of alcoholism. Transl Psychiatry (2014) 4:e391. doi:10.1038/tp.2014.29
65. Patel SD, Le-Niculescu H, Koller DL, Green SD, Lahiri DK, McMahon FJ, et al. Coming to grips with complex disorders: genetic risk prediction in bipolar disorder using panels of genes identified through convergent functional genomics. Am J Med Genet B Neuropsychiatr Genet (2010) 153B(4):850-77. doi:10.1002/ajmg.b.31087
66. Haldane M, Frangou S. New insights help define the pathophysiology of bipolar affective disorder: neuroimaging and neuropathology findings. Prog Neuropsychopharmacol Biol Psychiatry (2004) 28(6):943-60. doi:10.1016/j.pnpbp.2004.05.040
67. Wallis JD, Miller EK. Neuronal activity in primate dorsolateral and orbital prefrontal cortex during performance of a reward preference task. Eur J Neurosci (2003) 18(7):2069-81. doi:10.1046/j.1460-9568.2003.02922.x
68. Frangou S, Kington J, Raymont V, Shergill SS. Examining ventral and dorsal prefrontal function in bipolar disorder: a functional magnetic resonance imaging study. Eur Psychiatry (2008) 23(4):300-8. doi:10.1016/j.eurpsy.2007.05.002
69. Jogia J, Dima D, Kumari V, Frangou S. Frontopolar cortical inefficiency may underpin reward and working memory dysfunction in bipolar disorder. World J Biol Psychiatry (2012) 13(8):605-15. doi:10.3109/15622975.2011.585662
70. Young JW, van Enkhuizen J, Winstanley CA, Geyer MA. Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. J Psychopharmacol (2011) 25(7):934-43. doi:10.1177/0269881111400646
71. Camardese G, Di Giuda D, Di Nicola M, Cocciolillo F, Giordano A, Janiri L, et al. Imaging studies on dopamine transporter and depression: a review of literature and suggestions for future research. J Psychiatr Res (2014) 51:7-18. doi:10.1016/j.jpsychires.2013.12.006
72. Comings DE, Rosenthal RJ, Lesieur HR, Rugle LJ, Muhleman D, Chiu C, et al. A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics (1996) 6(3):223-34. doi:10.1097/00008571-199606000-00004
73. van Enkhuizen J, Geyer MA, Young JW. Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task: relevance to mania. Psychopharmacology (Berl) (2013) 225(3):661-74. doi:10.1007/s00213-012-2854-2
74. van Enkhuizen J, Henry BL, Minassian A, Perry W, Milienne-Petiot M, Higa KK, et al. Reduced dopamine transporter functioning induces high-reward risk-preference consistent with bipolar disorder. Neuropsychopharmacology (2014) 39(13):3112-22. doi:10.1038/npp.2014.170
75. Berk M, Dodd S, Kauer-Sant'anna M, Malhi GS, Bourin M, Kapczinski F, et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl (2007) 434:41-9. doi:10.1111/j.1600-0447.2007.01058.x
76. Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord (2009) 11(8):787-806. doi:10.1111/j.1399-5618.2009.00760.x
77. Diana M. The dopamine hypothesis of drug addiction and its potential therapeutic value. Front Psychiatry (2011) 2:64. doi:10.3389/fpsyt.2011.00064
78. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci (2012) 35(1):68-77. doi:10.1016/j.tins.2011.11.005
79. Hatzigiakoumis DS, Martinotti G, Giannantonio MD, Janiri L. Anhedonia and substance dependence: clinical correlates and treatment options. Front Psychiatry (2011) 2:10. doi:10.3389/fpsyt.2011.00010
80. Kirby LG, Zeeb FD, Winstanley CA. Contributions of serotonin in addiction vulnerability. Neuropharmacology (2011) 61(3):421-32. doi:10.1016/j.neuropharm.2011.03.022
81. Van den Oever MC, Spijker S, Smit AB. The synaptic pathology of drug addiction. Adv Exp Med Biol (2012) 970:469-91. doi:10.1007/978-3-7091-0932-8_21
82. Pettorruso M, De Risio L, Martinotti G, Di Nicola M, Ruggeri F, Conte G, et al. Targeting the glutamatergic system to treat pathological gambling: current evidence and future perspectives. Biomed Res Int (2014) 2014:109786. doi:10.1155/2014/109786
83. Pettorruso M, Martinotti G, Di Nicola M, Onofrj M, Di Giannantonio M, Conte G, et al. Amantadine in the treatment of pathological gambling: a case report. Front Psychiatry (2012) 3:102. doi:10.3389/fpsyt.2012.00102
84. Di Nicola M, De Risio L, Battaglia C, Camardese G, Tedeschi D, Mazza M, et al. Reduced hedonic capacity in euthymic bipolar subjects: a trait-like feature? J Affect Disord (2013) 147(1-3):446-50. doi:10.1016/j.jad.2012.10.004
85. McIntyre RS, McElroy SL, Konarski JZ, Soczynska JK, Bottas A, Castel S, et al. Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictions. J Clin Psychiatry (2007) 68(9):1352-7. doi:10.4088/JCP.v68n0905
86. Ibanez A, Cetkovich M, Petroni A, Urquina H, Baez S, Gonzalez-Gadea ML, et al. The neural basis of decision-making and reward processing in adults with euthymic bipolar disorder or attention-deficit/hyperactivity disorder (ADHD). PLoS One (2012) 7(5):e37306. doi:10.1371/journal.pone.0037306
87. Strakowski SM, Fleck DE, DelBello MP, Adler CM, Shear PK, Kotwal R, et al. Impulsivity across the course of bipolar disorder. Bipolar Disord (2010) 12(3):285-97. doi:10.1111/j.1399-5618.2010.00806.x
88. Pizzagalli DA, Goetz E, Ostacher M, Iosifescu DV, Perlis RH. Euthymic patients with bipolar disorder show decreased reward learning in a probabilistic reward task. Biol Psychiatry (2008) 64(2):162-8. doi:10.1016/j.biopsych.2007.12.001
89. Chandler RA, Wakeley J, Goodwin GM, Rogers RD. Altered risk-aversion and risk-seeking behavior in bipolar disorder. Biol Psychiatry (2009) 66(9):840-6. doi:10.1016/j.biopsych.2009.05.011
90. Mason L, O'Sullivan N, Blackburn M, Bentall R, El-Deredy W. I want it now! neural correlates of hypersensitivity to immediate reward in hypomania. Biol Psychiatry (2012) 71(6):530-7. doi:10.1016/j.biopsych.2011.10.008
91. Bizzarri JV, Sbrana A, Rucci P, Ravani L, Massei GJ, Gonnelli C, et al. The spectrum of substance abuse in bipolar disorder: reasons for use, sensation seeking and substance sensitivity. Bipolar Disord (2007) 9(3):213-20. doi:10.1111/j.1399-5618.2007.00383.x
92. Edge MD, Miller CJ, Muhtadie L, Johnson SL, Carver CS, Marquinez N, et al. People with bipolar I disorder report avoiding rewarding activities and dampening positive emotion. J Affect Disord (2013) 146(3):407-13. doi:10.1016/j.jad.2012.07.027
93. Nusslock R, Almeida JR, Forbes EE, Versace A, Frank E, Labarbara EJ, et al. Waiting to win: elevated striatal and orbitofrontal cortical activity during reward anticipation in euthymic bipolar disorder adults. Bipolar Disord (2012) 14(3):249-60. doi:10.1111/j.1399-5618.2012.01012.x
94. Linke J, Sonnekes C, Wessa M. Sensitivity to positive and negative feedback in euthymic patients with bipolar I disorder: the last episode makes the difference. Bipolar Disord (2011) 13(7-8):638-50. doi:10.1111/j.1399-5618.2011.00956.x
95. Yechiam E, Hayden EP, Bodkins M, O'Donnell BF, Hetrick WP. Decision making in bipolar disorder: a cognitive modeling approach. Psychiatry Res (2008) 161(2):142-52. doi:10.1016/j.psychres.2007.07.001
96. Pizzagalli DA. Depression, stress, and anhedonia: toward a synthesis and integrated model. Annu Rev Clin Psychol (2014) 10:393-423. doi:10.1146/annurev-clinpsy-050212-185606
97. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci (2008) 1141:105-30. doi:10.1196/annals.1441.030
98. Lovallo WR. Cortisol secretion patterns in addiction and addiction risk. Int J Psychophysiol (2006) 59(3):195-202. doi:10.1016/j.ijpsycho.2005.10.007
99. Lijffijt M, Hu K, Swann AC. Stress modulates illness-course of substance use disorders: a translational review. Front Psychiatry (2014) 5:83. doi:10.3389/fpsyt.2014.00083
100. Levy YZ, Levy DJ, Barto AG, Meyer JS. A computational hypothesis for allostasis: delineation of substance dependence, conventional therapies, and alternative treatments. Front Psychiatry (2013) 4:167. doi:10.3389/fpsyt.2013.00167
101. Post RM, Kalivas P. Bipolar disorder and substance misuse: pathological and therapeutic implications of their comorbidity and cross-sensitisation. Br J Psychiatry (2013) 202(3):172-6. doi:10.1192/bjp.bp.112.116855
102. Azorin JM, Bellivier F, Kaladjian A, Adida M, Belzeaux R, Fakra E, et al. Characteristics and profiles of bipolar I patients according to age-at-onset: findings from an admixture analysis. J Affect Disord (2013) 150(3):993-1000. doi:10.1016/j.jad.2013.05.026
103. Pope MA, Joober R, Malla AK. Diagnostic stability of first-episode psychotic disorders and persistence of comorbid psychiatric disorders over 1 year. Can J Psychiatry (2013) 58(10):588-94.
104. Goldstein BI, Strober M, Axelson D, Goldstein TR, Gill MK, Hower H, et al. Predictors of first-onset substance use disorders during the prospective course of bipolar spectrum disorders in adolescents. J Am Acad Child Adolesc Psychiatry (2013) 52(10):1026-37. doi:10.1016/j.jaac.2013.07.009
105. Kenneson A, Funderburk JS, Maisto SA. Risk factors for secondary substance use disorders in people with childhood and adolescent-onset bipolar disorder: opportunities for prevention. Compr Psychiatry (2013) 54(5):439-46. doi:10.1016/j.comppsych.2012.12.008
106. Duffy A, Horrocks J, Milin R, Doucette S, Persson G, Grof P. Adolescent substance use disorder during the early stages of bipolar disorder: a prospective high-risk study. J Affect Disord (2012) 142(1-3):57-64. doi:10.1016/j.jad.2012.04.010
107. Do EK, Mezuk B. Comorbidity between hypomania and substance use disorders. J Affect Disord (2013) 150(3):974-80. doi:10.1016/j.jad.2013.05.023
108. Prisciandaro JJ, DeSantis SM, Chiuzan C, Brown DG, Brady KT, Tolliver BK. Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate. Alcohol Clin Exp Res (2012) 36(3):490-6. doi:10.1111/j.1530-0277.2011.01645.x
109. Saddichha S, Prakash R, Sinha BN, Khess CR. Perceived reasons for and consequences of substance abuse among patients with psychosis. Prim Care Companion J Clin Psychiatry (2010) 12(5):e1-7. doi:10.4088/PCC.09m00926gry
110. Pettersen H, Ruud T, Ravndal E, Landheim A. Walking the fine line: self-reported reasons for substance use in persons with severe mental illness. Int J Qual Stud Health Well-being (2013) 8:21968. doi:10.3402/qhw.v8i0.21968
111. Rømer Thomsen K, Callesen MB, Linnet J, Kringelbach ML, Møller A. Severity of gambling is associated with severity of depressive symptoms in pathological gamblers. Behav Pharmacol (2009) 20(5-6):527-36. doi:10.1097/FBP.0b013e3283305e7a
112. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry (1985) 142(11):1259-64.
113. Robinson LJ, Thompson JM, Gallagher P, Goswami U, Young AH, Ferrier IN, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord (2006) 93(1-3):105-15. doi:10.1016/j.jad.2006.02.016
114. Bally N, Zullino D, Aubry JM. Cannabis use and first manic episode. J Affect Disord (2014) 165:103-8. doi:10.1016/j.jad.2014.04.038
115. Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. Psychiatry Res (2013) 209(3):459-65. doi:10.1016/j.psychres.2012.12.014
116. Baigent M. Managing patients with dual diagnosis in psychiatric practice. Curr Opin Psychiatry (2012) 25(3):201-5. doi:10.1097/YCO.0b013e3283523d3d
117. Di Nicola M, Sala L, Romo L, Catalano V, Even C, Dubertret C, et al. Adult attention-deficit/hyperactivity disorder in major depressed and bipolar subjects: role of personality traits and clinical implications. Eur Arch Psychiatry Clin Neurosci (2014) 264(5):391-400. doi:10.1007/s00406-013-0456-6
118. Perugi G, Ceraudo G, Vannucchi G, Rizzato S, Toni C, Dell'Osso L. Attention deficit/hyperactivity disorder symptoms in Italian bipolar adult patients: a preliminary report. J Affect Disord (2013) 149(1-3):430-4. doi:10.1016/j.jad.2012.12.010
119. Sala R, Goldstein BI, Wang S, Blanco C. Childhood maltreatment and the course of bipolar disorders among adults: epidemiologic evidence of dose-response effects. J Affect Disord (2014) 165:74-80. doi:10.1016/j.jad.2014.04.035
120. Jones SH, Barrowclough C, Allott R, Day C, Earnshaw P, Wilson I. Integrated motivational interviewing and cognitive-behavioural therapy for bipolar disorder with comorbid substance use. Clin Psychol Psychother (2011) 18(5):426-37. doi:10.1002/cpp.783
121. Gaudiano BA, Weinstock LM, Miller IW. Improving treatment adherence in patients with bipolar disorder and substance abuse: rationale and initial development of a novel psychosocial approach. J Psychiatr Pract (2011) 17(1):5-20. doi:10.1097/01.pra.0000393840.18099.d6
122. Horsfall J, Cleary M, Hunt GE, Walter G. Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence. Harv Rev Psychiatry (2009) 17(1):24-34. doi:10.1080/10673220902724599
123. Murru A, Pacchiarotti I, Amann BL, Nivoli AM, Vieta E, Colom F. Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. J Affect Disord (2013) 151(3):1003-8. doi:10.1016/j.jad.2013.08.026
124. Juster RP, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci Biobehav Rev (2010) 35(1):2-16. doi:10.1016/j.neubiorev.2009.10.002
125. Goldstein BI, Bukstein OG. Comorbid substance use disorders among youth with bipolar disorder: opportunities for early identification and prevention. J Clin Psychiatry (2010) 71(3):348-58. doi:10.4088/JCP.09r05222gry
126. Langas AM, Malt UF, Opjordsmoen S. Independent versus substance-induced major depressive disorders in first-admission patients with substance use disorders: an exploratory study. J Affect Disord (2013) 144(3):279-83. doi:10.1016/j.jad.2012.10.008
127. Quello SB, Brady KT, Sonne SC. Mood disorders and substance use disorder: a complex comorbidity. Sci Pract Perspect (2005) 3(1):13-21. doi:10.1151/spp053113
128. Li CS, Sinha R. Inhibitory control and emotional stress regulation: neuroimaging evidence for frontal-limbic dysfunction in psycho-stimulant addiction. Neurosci Biobehav Rev (2008) 32(3):581-97. doi:10.1016/j.neubiorev.2007.10.003
129. Kenneson A, Funderburk JS, Maisto SA. Substance use disorders increase the odds of subsequent mood disorders. Drug Alcohol Depend (2013) 133(2):338-43. doi:10.1016/j.drugalcdep.2013.06.011
130. Pettinati HM, O'Brien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry (2013) 170(1):23-30. doi:10.1176/appi.ajp.2012.12010112
131. Marchese G, Scheggi S, Secci ME, De Montis MG, Gambarana C. Anti-anhedonic activity of long-term lithium treatment in rats exposed to repeated unavoidable stress. Int J Neuropsychopharmacol (2013) 16(7):1611-21. doi:10.1017/S1461145712001654
132. Orsetti M, Canonico PL, Dellarole A, Colella L, Di Brisco F, Ghi P. Quetiapine prevents anhedonia induced by acute or chronic stress. Neuropsychopharmacology (2007) 32(8):1783-90. doi:10.1038/sj.npp.1301291
133. Marston HM, Martin FD, Papp M, Gold L, Wong EH, Shahid M. Attenuation of chronic mild stress-induced 'anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation. J Psychopharmacol (2011) 25(10):1388-98. doi:10.1177/0269881110376684
134. Mazza M, Squillacioti MR, Pecora RD, Janiri L, Bria P. Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients. Psychiatry Res (2009) 165(1-2):193-6. doi:10.1016/j.psychres.2008.05.003
135. Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone M, Janiri L. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol (2008) 23(5):417-24. doi:10.1002/hup.944
136. Prisciandaro JJ, Brown DG, Brady KT, Tolliver BK. Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: results of a randomized controlled trial. Psychiatry Res (2011) 188(3):361-5. doi:10.1016/j.psychres.2011.04.030
137. Di Nicola M, Martinotti G, Mazza M, Tedeschi D, Pozzi G, Janiri L. Quetiapine as add-on treatment for bipolar I disorder with comorbid compulsive buying and physical exercise addiction. Prog Neuropsychopharmacol Biol Psychiatry (2010) 34(4):713-4. doi:10.1016/j.pnpbp.2010.03.013
138. Janiri L, Martinotti G, Di Nicola M. Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: results from a pilot study. J Clin Psychopharmacol (2007) 27(5):519-20. doi:10.1097/JCP.0b013e318150c841
139. Di Nicola M, De Risio L, Pettorruso M, Caselli G, De Crescenzo F, Swierkosz-Lenart K, et al. Bipolar disorder and gambling disorder comorbidity: current evidence and implications for pharmacological treatment. J Affect Disord (2014) 167:285-98. doi:10.1016/j.jad.2014.06.023
140. Beaulieu S, Saury S, Sareen J, Tremblay J, Schütz CG, McIntyre RS, et al. The canadian network for mood and anxiety treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. Ann Clin Psychiatry (2012) 24(1):38-55.
141. Sani G, Kotzalidis GD, Vöhringer P, Pucci D, Simonetti A, Manfredi G, et al. Effectiveness of short-term olanzapine in patients with bipolar I disorder, with or without comorbidity with substance use disorder. J Clin Psychopharmacol (2013) 33(2):231-5. doi:10.1097/JCP.0b013e318287019c
142. Machado-Vieira R, Ibrahim L, Henter ID, Zarate CA Jr. Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav (2012) 100(4):678-87. doi:10.1016/j.pbb.2011.09.010
143. Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav (2012) 100(4):801-10. doi:10.1016/j.pbb.2011.04.015